Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 145

Results For "MD"

1834 News Found

Athos announces research collaboration to advance precision medicine in inflammatory bowel disease
News | July 13, 2022

Athos announces research collaboration to advance precision medicine in inflammatory bowel disease

Athos will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples


MFine and LifeCell form JV ‘LifeWell’
Digitisation | July 11, 2022

MFine and LifeCell form JV ‘LifeWell’

LifeWell Raises USD 80M from OrbiMed to Build Large Scale Healthcare Delivery Platform with Full stack Diagnostics~


Capnopharm to acquire operational assets of Capnomed
News | July 10, 2022

Capnopharm to acquire operational assets of Capnomed

Capnomed successfully introduced the medical device Capnopen, the gold standard of laparoscopic nebulizers.


CEPI and Codiak BioSciences partner to develop protective Betacoronavirus vaccine
News | July 06, 2022

CEPI and Codiak BioSciences partner to develop protective Betacoronavirus vaccine

CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.


ART Fertility Clinics appoints Dr. Somesh Mittal as CEO, India
People | July 05, 2022

ART Fertility Clinics appoints Dr. Somesh Mittal as CEO, India

Mittal has previously managed Multiple backed Vikram Hospital as CEO and was associated with Fortis Escorts Heart Institute as zonal director.


50% of heart attacks now happens in Indians below 50 years: says Expert
Public Health | July 05, 2022

50% of heart attacks now happens in Indians below 50 years: says Expert

Younger Indians have a 10 times higher rate of heart attack


Sanofi flu vaccines licensed and approved for 2022-2023 influenza season
Drug Approval | July 05, 2022

Sanofi flu vaccines licensed and approved for 2022-2023 influenza season

Sanofi will begin to ship their vaccines helping to ensure more people will be immunized


OliX Pharmaceuticals submits application to U.S. FDA to evaluate safety and tolerability of OLX10212
Drug Approval | July 04, 2022

OliX Pharmaceuticals submits application to U.S. FDA to evaluate safety and tolerability of OLX10212

The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.


Clinical study of PD-L1 antibody ASC22 for cure of HIV completes first patient dosing
Clinical Trials | July 04, 2022

Clinical study of PD-L1 antibody ASC22 for cure of HIV completes first patient dosing

Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection